Some physicians may be reluctant to use growth factor support because of concerns about compromising outcome during curative treatment, given that erythropoietin receptors have been reported to be present on some breast cancer cells 25,26, and endogenous erythropoietin may inhibit hypoxia-induced apoptosis of breast cancer cells 27. Here, EPOR is linked to breast carcinoma.